FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Banking

Why the World’s Wealthiest Are Diversifying Across Borders

London — 18th March 2026 — Global Citizen Solutions (“GCS”), a leading advisory firm in citizenship and residency...
FinTech

Marquis Software Confirms Data Theft of 672K Bank Customers in Ransomware Attack

The cyberattack raises concerns about data security in the banking sector.Highlights: Marquis Software data breach impacts 672,000 bank...
FinTech

NCR Strengthens Focus by Offloading Japanese Bank Technology Business to NTT Data

NCR transfers its Japanese banking tech operations to enhance strategic focus.Highlights: NCR sells its Japanese banking technology business...
FinTech

Agentic Workforce Initiative Enhances Financial Institutions’ Performance

New platform aims to optimize operations for banks and financial service providers.Highlights: New Agentic Workforce initiative launched for...